Calliditas Therapeutics AB (publ) reaffirmed earnings guidance for the year ending December 31, 2024. For the year, the company expects continued revenue growth: total net sales are estimated to be USD 150-180 million for the year ending December 31, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
204.8 SEK | +0.10% | -0.29% | +61.13% |
Jun. 18 | Calliditas Therapeutics Gets US Patent for Cancer Treatment Candidate | MT |
Jun. 18 | Calliditas Therapeutics Secures US Patent for Cancer Treatment Inhibitor | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+61.13% | 1.04B | |
+15.72% | 77.46B | |
+13.65% | 8.94B | |
-24.30% | 4.28B | |
+12.79% | 4.18B | |
+31.45% | 4.11B | |
+10.97% | 2.23B | |
-30.57% | 2.06B | |
+8.99% | 1.97B | |
-45.76% | 1.69B |
- Stock Market
- Equities
- CALTX Stock
- News Calliditas Therapeutics AB
- Calliditas Therapeutics AB Reaffirms Earnings Guidance for the Year Ending December 31, 2024